-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Insmed, Lowers Price Target to $207

Benzinga·09/30/2026 15:39:06
Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.